Gilbert综合征与UGT1A1基因突变的研究进展
Research Progress of Gilbert Syndrome and UGT1A1 Gene Mutation
DOI: 10.12677/ACM.2023.133524, PDF,    科研立项经费支持
作者: 高梓萌:西安医学院研究生处,陕西 西安;李亚绒*:西安市儿童医院感染科,陕西 西安
关键词: Gilbert综合征UGT1A1基因突变尿苷二磷酸葡萄糖醛酸转移酶内源性抗氧化剂有害有益Gilbert Syndrome UGT1A1 Gene Mutation UGT Endogenous Antioxidants Harm Benefit
摘要: Gilbert综合征(Gilbert syndrome, GS)是一种以反复、轻度高间接胆红素血症为特征的常染色体隐性遗传病,尿苷二磷酸葡糖醛酸基转移酶1A1 (uridine diphosphate glucuronosyl transferase 1A1, UGT1A1)基因突变所导致UGT1A1酶的活性降低是Gilbert综合征的主要发病机制。GS诊断主要依据临床表现及实验室检查,在排除溶血及其他肝脏疾病后进行UGT1A1基因检测确诊。UGT1A1的基因突变是确定不明来源的高胆红素血症病因的重要步骤,分子诊断避免了肝穿刺等侵袭性的诊断方法,在疾病早期即可建立正确的治疗程序。除肝脏疾病外,GS患者中UGT1A1基因突变还参与其他多系统疾病的发病及相关药物代谢过程。本文对GS诊治及UGT1A1基因突变与GS关系研究进展进行综述。
Abstract: Gilbert syndrome (GS) is an autosomal recessive genetic disorder characterized by recurrent and mild hyperindirect bilirubinemia. The decrease in the activity of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene mutation is the main pathogenesis of Gilbert syndrome. The diag-nosis of GS was mainly based on clinical manifestations and laboratory examination, and was con-firmed by UGT1A1 gene test after hemolysis and other liver diseases were excluded. The mutation of UGT1A1 is an important step in identifying the etiology of hyperbilirubinemia of unknown origin. Molecular diagnosis avoids aggressive diagnostic methods such as liver puncture, and the correct treatment procedure can be established early in the disease. In addition to liver disease, UGT1A1 gene mutation in GS patients is also involved in the pathogenesis of other multi-system diseases and related drug metabolism. In this paper, the diagnosis and treatment of GS and the relationship be-tween UGT1A1 gene mutation and GS were reviewed.
文章引用:高梓萌, 李亚绒. Gilbert综合征与UGT1A1基因突变的研究进展[J]. 临床医学进展, 2023, 13(3): 3657-3662. https://doi.org/10.12677/ACM.2023.133524

参考文献

[1] Memon, N., Weinberger, B.I., Hegyi, T., et al. (2016) Inherited Disorders of Bilirubin Clearance. Pediatric Research, 79, 378-386. [Google Scholar] [CrossRef] [PubMed]
[2] Zhang, M., Wang, H., Huang, Y., et al. (2021) Compound Het-erozygous UGT1A1*28 and UGT1A1*6 or Single Homozygous UGT1A1*28 Are Major Genotypes Associated with Gilbert’s Syndrome in Chinese Han People. Gene, 781, Article ID: 145526. [Google Scholar] [CrossRef] [PubMed]
[3] Maruo, Y., Nakahara, S., Yanagi, T., et al. (2016) Genotype of UGT1A1 and Phenotype Correlation between Crigler-Najjar Syndrome Type II and Gilbert Syndrome. Journal of Gas-troenterology and Hepatology, 31, 403-408. [Google Scholar] [CrossRef] [PubMed]
[4] 邓玉婷, 魏民华, 周俊英. Gilbert综合征研究进展[J]. 实用肝脏病杂志, 2021, 24(2): 156-159.
[5] Mi, X.X., Yan, J., Ma, X.J., et al. (2019) Analysis of the UGT1A1 Genotype in Hyperbili-rubinemia Patients: Differences in Allele Frequency and Distribution. BioMed Research International, 2019, Article ID: 6272174. [Google Scholar] [CrossRef] [PubMed]
[6] Kamal, S., Abdelhakam, S., Ghoraba, D., et al. (2019) The Frequency, Clinical Course, and Health Related Quality of Life in Adults with Gilbert’s Syndrome: A Longitudinal Study. BMC Gastroenterology, 19, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[7] Sun, L., Li, M., Zhang, L., et al. (2017) Differences in UGT1A1 Gene Mutations and Pathological Liver Changes between Chinese Patients with Gilbert Syndrome and Crigler-Najjar Syndrome Type II. Medicine, 96, e8620. [Google Scholar] [CrossRef
[8] 张梦, 齐俊英. UGT1A1基因的分子流行病学及其在Gilbert综合征诊断中的价值[J]. 国际流行病学传染病学杂志, 2019, 46(5): 407-410.
[9] 向国卿, 孙福荣, 王炳元. 吉尔伯特综合征: 高胆红素血症是敌人还是朋友[J]. 中华肝脏病杂志, 2021, 29(10): 1024-1027.
[10] 张颖, 金玉. 遗传性非结合性高胆红素血症研究进展[J]. 中国现代医生, 2022, 60(19): 99-102.
[11] Maruo, Y., D’Addario, C., Mori, A., et al. (2004) Two Linked Polymorphic Mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the Principal Cause of Gilbert Syndrome. Human Genetics, 115, 525-526. [Google Scholar] [CrossRef] [PubMed]
[12] Huang, M.J., Chen, Y.C., Huang, Y.Y., et al. (2019) Effect of UDP-Glucuronosyltransferase 1A1 Activity on Risk for Developing Gilbert’s Syndrome. The Kaohsiung Journal of Medical Sciences, 35, 432-439. [Google Scholar] [CrossRef] [PubMed]
[13] Matsui, K., Maruo, Y., Sato, H., et al. (2010) Combined Effect of Regu-latory Polymorphisms on Transcription of UGT1A1 as a Cause of Gilbert Syndrome. BMC Gastroenterology, 10, Arti-cle No. 57. [Google Scholar] [CrossRef
[14] 梁晨, 罗磊, 白洁. Gilbert综合征和Crigler-Najjar综合征相关尿苷二磷酸葡糖醛酸转移酶A1基因突变位点特征分析[J]. 中华肝脏病杂志, 2020, 28(5): 428-433.
[15] 鲁杰. 先天性非溶血性黄疸的研究进展[J]. 临床肝胆病杂志, 2021, 37(1): 216-220.
[16] Wagner, K.H., Shiels, R.G., Lang, C.A., et al. (2018) Diagnostic Criteria and Contributors to Gilbert’s Syndrome. Critical Reviews in Clinical Laboratory Sciences, 55, 129-139. [Google Scholar] [CrossRef] [PubMed]
[17] 张梦, 李维娜, 陈广, 等. UGT1A1基因检测在Gilbert综合征中的诊断价值分析[J]. 中华肝脏病杂志, 2021, 29(2): 143-149.
[18] Erlinger, S., Arias, I.M. and Dhumeaux, D. (2014) Inherited Disorders of Bilirubin Transport and Conjugation: New Insights into Molecular Mechanisms and Consequences. Gastroenterology, 146, 1625-1638. [Google Scholar] [CrossRef] [PubMed]
[19] 李露锋, 邓国宏, 毛青. Gilbert综合征UGT1A1致病变异的连锁关系研究[J]. 第三军医大学学报, 2020, 42(2): 168-175.
[20] Abuduxikuer, K., Fang, L.J., Li, L.T., et al. (2018) UGT1A1 Genotypes and Unconjugated Hyperbilirubinemia Phenotypes in Post-Neonatal Chinese Children: A Retro-spective Analysis and Quantitative Correlation. Medicine (Baltimore), 97, e13576. [Google Scholar] [CrossRef
[21] 郭丽萍, 张国淳, 陈博, 等. UGT1A1基因多态性与乳腺癌临床病理特征的相关性[J]. 实用医学杂志, 2020, 36(1): 1-5.
[22] Adegoke, O.J., Shu, X.O., Gao, Y.T., et al. (2004) Genetic Polymorphisms in Uridine Diphospho-Glucuronosyltransferase 1A1 (UGT1A1) and Risk of Breast Cancer. Breast Cancer Research and Treatment, 85, 239-245. [Google Scholar] [CrossRef
[23] 邸晓辉, 许茜, 宋丽雪, 等. 尿苷二磷酸葡萄糖醛酸转移酶1A1和2B7基因多态性与结直肠癌的相关性研究[J]. 解放军药学学报, 2014, 30(4): 292-295.
[24] 梁晨, 白丽, 郑素军. Gilbert综合征UGT1A1基因突变特征及对肝脏和肝外系统的影响[J]. 临床肝胆病杂志, 2019, 35(7): 1632-1635.
[25] Nelson, R.S., Seligson, N.D., Bottiglieri, S., et al. (2021) UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel), 13, 1566. [Google Scholar] [CrossRef] [PubMed]
[26] 印亚双, 王培香, 段京莉. 伊立替康致3-4级中性粒细胞减少与UGT1A1基因多态性相关性的Meta分析[J]. 中国药房, 2017, 28(18): 2523-2528.
[27] 吴燕子, 陈晓燚, 薛源, 等. UGT1A1基因多态性与伊立替康所致不良反应的相关性分析[J]. 药学与临床研究, 2020, 28(1): 24-27.
[28] Takano, M. and Sugiyama, T. (2017) UGT1A1 Polymorphisms in Cancer: Impact on Irinotecan Treatment. Pharmacogenomics and Personalized Medicine, 10, 61-68. [Google Scholar] [CrossRef
[29] Hulshof, E.C., Deenen, M.J., Guchelaar, H.J., et al. (2020) Pre-Therapeutic UGT1A1 Genotyping to Reduce the Risk of Irinotec-an-Induced Severe Toxicity: Ready for Prime Time. European Journal of Cancer, 141, 9-20. [Google Scholar] [CrossRef] [PubMed]
[30] Lee, J.S., Wang, J., Martin, M., et al. (2011) Genetic Variation in UGT1A1 Typical of Gilbert Syndrome Is Associated with Unconjugated Hyperbilirubinemia in Patients Receiving To-cilizumab. Pharmacogenetics and Genomics, 21, 365-374. [Google Scholar] [CrossRef
[31] King, D. and Armstrong, M.J. (2019) Overview of Gilbert’s Syndrome. Drug and Therapeutics Bulletin, 57, 27-31. [Google Scholar] [CrossRef] [PubMed]
[32] Mimura, Y., Maruo, Y., Ohta, Y., et al. (2011) Effect of Common Exon Variant (p.P364L) on Drug Glucuronidation by the Human UDP-Glucuronosyltransferase 1 Family. Basic & Clin-ical Pharmacology & Toxicology, 109, 486-493. [Google Scholar] [CrossRef] [PubMed]
[33] 方仲蓉, 王伟鹏. 丙泊酚输注综合征[J]. 心血管外科杂志(电子版), 2013, 2(4): 31-36.
[34] Bulmer, A.C., Bakrania, B., Du Toit, E.F., et al. (2018) Bilirubin Acts as a Mul-tipotent Guardian of Cardiovascular Integrity: More than Just a Radical Idea. The American Journal of Physiology-Heart and Circulatory Physiology, 315, H429-H447. [Google Scholar] [CrossRef] [PubMed]